Page 154 - Read Online

Dastidar et al. Vessel Plus 2020;4:14 Vessel Plus
DOI: 10.20517/2574-1209.2019.36

Review Open Access

Tumour vasculature targeted anti-cancer therapy

Debabrata Ghosh Dastidar , Dipanjan Ghosh , Gopal Chakrabarti 2
2
1,2
1 Guru Nanak Institute of Pharmaceutical Science and Technology, West Bengal, Kolkata 700114, India.
2 Department of Biotechnology and Dr. B. C. Guha Centre for Genetic Engineering and Biotechnology, University of Calcutta,
Kolkata 700019, India.
Correspondence to: Debabrata Ghosh Dastidar, Assistant Professor, Division of Pharmaceutics, Guru Nanak Institute of
Pharmaceutical Science & Technology, 157/F Nilguanj Road, Panihati, Kolkata 700114, West Bengal, India.
E-mail: debabrata.ghoshdastidar@gnipst.ac.in
How to cite this article: Dastidar DG, Ghosh D, Chakrabarti G. Tumour vasculature targeted anti-cancer therapy. Vessel Plus
2020;4:14. http://dx.doi.org/10.20517/2574-1209.2019.36
Received: 26 Dec 2019 First Decision: 8 Feb 2020 Revised: 16 Feb 2020 Accepted: 7 Apr 2020 Published: 27 May 2020

Science Editor: Narasimham L. Parinandi Copy Editor: Jing-Wen Zhang Production Editor: Jing Yu

Abstract
Received: First Decision: Revised: Accepted: Published: x The tumour vasculature plays an important role in tumour growth and metastasis. Tumour angiogenesis provides
more oxygen and nutrients to growing tumour cells, is not as tightly regulated as embryonic angiogenesis, and
Science Editor: Copy Editor: Production Editor: Jing Yu
do not follow any hierarchically ordered pattern. The heterogeneity of the vasculature, high interstitial fluid
pressure, poor extravasation due to sluggish blood flow, and larger distances between exchange vessels are
potential barriers to the delivery of therapeutic agents to tumours. The prevention of angiogenesis, normalization
of tumour vasculature, and enhancement of blood perfusion through the use of monoclonal antibodies against
receptor proteins that are overexpressed on proangiogenic tumour cells, and improved, tumour-targeted delivery
of therapeutic agents can all be achieved using nanocarriers of appropriate size. Nanomedicines such as polymeric
nanoparticles, lipid nanoparticles, micelles, mesoporous silica particles, metal nanoparticles, noisomes, and
liposomes have been developed for the delivery of anticancer drugs in combination with antiangiogenic agents.
Amongst them, liposomal delivery systems are mostly approved by the FDA for clinical use. In this review, the
molecular pathways of tumour angiogenesis, the physiology of tumour vasculature, barriers to tumour-targeted
delivery of therapeutic agents, and the different strategies to overcome these barriers are discussed.

Keywords: Tumour, angiogenesis, antiangiogenic drug, targeted drug delivery, nanoparticle, normalization of
tumour vasculature, sonoporation, hyperthermia

© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.vpjournal.net